TRT and high hematocrit: what actually happens when doctors stop treatment

What did @the.tudca.king actually say?

The creator describes a real clinical scenario: a TRT patient's hematocrit rises, the doctor recommends blood donation to bring it down, then the patient gets disqualified from donating, leaving them stuck. His conclusion: "there really aren't any other options" beyond a supplement called Hematflow. That framing is where the trouble starts, and it's worth unpacking carefully.

To be fair, the setup is accurate. Testosterone does raise hematocrit in a meaningful percentage of users, blood donation is commonly used to manage it, and some patients do get disqualified from donation programs. So the clinical problem he's describing is real. The solution he arrives at is the part that deserves scrutiny.

Does the science back this up?

Testosterone-induced erythrocytosis is well-documented. Studies estimate 10-25% of men on TRT develop hematocrit above 52%, which is the threshold most clinicians watch. A 2021 paper by Bachman et al. in the Journal of Clinical Endocrinology and Metabolism confirmed that injectable testosterone formulations carry higher erythrocytosis risk than gels or patches, largely due to peak androgen surges.

Blood donation as a management tool is standard practice and works mechanically: it removes red blood cells and drops hematocrit quickly. The problem is that frequent therapeutic phlebotomy creates iron deficiency in some patients, and yes, donation centers can and do disqualify donors who appear to be donating for therapeutic rather than altruistic reasons. That disqualification issue is real and documented in clinical commentary, including work by Spitzer et al. (2019, Urology).

What is not backed by peer-reviewed evidence is the claim that a commercial supplement fills the gap left when phlebotomy is unavailable. No randomized controlled trial exists demonstrating that Hematflow or similar products reliably reduce hematocrit in TRT-induced erythrocytosis.

What did they get wrong (or right)?

The creator gets credit for identifying a genuine clinical gap. Patients who are disqualified from donation and whose doctors won't adjust their protocol do face a real problem. That part is accurate and often under-discussed in TRT communities.

Where this goes wrong: the phrase "there really aren't any other options" is flatly incorrect. It ignores several evidence-based interventions. Dose reduction or switching from weekly injections to more frequent smaller doses flattens androgen peaks and demonstrably reduces erythrocytosis risk. Switching delivery method from injectable to transdermal is another option with clinical support. Therapeutic phlebotomy through a physician's office, outside of a blood bank, remains available to most patients. Temporary testosterone cessation is also an option, however unpleasant.

Describing a branded supplement as the answer to a problem where several physician-directed options exist is misleading, regardless of whether the supplement has any biological plausibility. The creator has a commercial interest in Hematflow, which he does not disclose in this clip.

What should you actually know?

If your hematocrit is rising on TRT, this is a conversation to have with a prescribing physician, not a supplement decision. Hematocrit above 54% is associated with increased blood viscosity, and while the cardiovascular risk evidence is debated, a 2023 meta-analysis by Wallis et al. in European Urology noted that clinicians should treat elevated hematocrit as a dose-management signal, not a supplement indication.

Your actual options if blood donation is unavailable include: asking your provider to reduce dose or increase injection frequency to reduce androgen peaks, asking about switching to a gel or cream formulation, requesting in-office therapeutic phlebotomy, or evaluating whether your current protocol is appropriate for your baseline.

• Hematocrit above 52% should prompt a protocol review, not just a workaround.
• No supplement has FDA clearance or strong RCT data for managing TRT-induced erythrocytosis.
• The claim that patients are "out of options" without Hematflow is not supported by clinical guidelines.
• The creator sells Hematflow and does not disclose that in this video.

The bottom line

The clinical scenario described here is legitimate and the problem of donation disqualification is real. But presenting a commercial supplement as the primary solution, while omitting physician-directed alternatives, crosses from educational content into product marketing. Patients deserve to know those alternatives exist before reaching for a bottle.